These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 30402748

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases.
    Tanaka K, Fujita N, Hibino S.
    CEN Case Rep; 2020 Aug; 9(3):247-251. PubMed ID: 32240525
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.
    Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome.
    González CC, López-Jiménez V, Vázquez-Sánchez T, Vázquez-Sánchez E, Cabello M, Hernández-Marrero D.
    Transplant Proc; 2022 Dec; 54(1):25-26. PubMed ID: 34906374
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [Abstract] [Full Text] [Related]

  • 29. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
    Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M.
    Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
    [Abstract] [Full Text] [Related]

  • 30. Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.
    Levi C, Frémeaux-Bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-Soussan R.
    Transplantation; 2017 Dec; 101(12):2924-2930. PubMed ID: 28858176
    [Abstract] [Full Text] [Related]

  • 31. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A, Nayer A, Haas CS.
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.
    Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O.
    Nephrol Dial Transplant; 2020 Feb 01; 35(2):298-303. PubMed ID: 29992261
    [Abstract] [Full Text] [Related]

  • 34. [Recurrent atypical hemolytic uremic syndrome after renal transplantation: treatment with eculizumab].
    Latzke AB, Fernández P, Chiurchiu C, Sarmantano D, De Arteaga J, Douthat W, De la Fuente J.
    Medicina (B Aires); 2018 Feb 01; 78(2):119-122. PubMed ID: 29659362
    [Abstract] [Full Text] [Related]

  • 35. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K, Seeman T.
    Transplant Proc; 2018 Apr 01; 50(3):967-970. PubMed ID: 29661469
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.
    Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C, French Study Group for Atypical HUS.
    Am J Transplant; 2012 Dec 01; 12(12):3337-54. PubMed ID: 22958221
    [Abstract] [Full Text] [Related]

  • 38. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome.
    Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, van den Heuvel LP, Mollnes TE.
    Clin Immunol; 2015 Oct 01; 160(2):237-43. PubMed ID: 26111482
    [Abstract] [Full Text] [Related]

  • 39. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S, AlDabbagh A, Alamoudi A, Almowarey M, Akl A.
    CEN Case Rep; 2019 May 01; 8(2):139-143. PubMed ID: 30715674
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.